Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Cipla Ltd ( (IN:CIPLA) ).
Cipla has disclosed that its key U.S. product Lanreotide Injection faces a temporary supply disruption after the USFDA issued nine inspectional observations for its exclusive supplier, Pharmathen International S.A., following an inspection of Pharmathen’s Rodopi, Greece facility. Production at Pharmathen has been paused to support remediation, resulting in limited Lanreotide availability until manufacturing restarts, with re-supply to the U.S. market expected in the first half of FY 2026-27; the company is monitoring inventories closely and has pledged to restore stable and reliable supply, a development with potential implications for its U.S. revenue and for patients reliant on the drug.
More about Cipla Ltd
Cipla Ltd is an Indian pharmaceutical company that develops, manufactures and markets a wide range of medicines, with a significant presence in the US generics market through its subsidiary Cipla USA Inc. Among its key U.S. offerings is Lanreotide Injection, which ranks among the company’s top three products in that market, underscoring its strategic importance to Cipla’s international portfolio.
Average Trading Volume: 119,149
Technical Sentiment Signal: Hold
Current Market Cap: 1184.2B INR
Learn more about CIPLA stock on TipRanks’ Stock Analysis page.